Вы искали: pneumokockpolysackaridvaccin (Шведский - Английский)

konjugerat pneumokockpolysackaridvaccin (adsorberat)
pneumococcal polysaccharide conjugate vaccine (adsorbed)

vuxna som tidigare vaccinerats med 23-valent pneumokockpolysackaridvaccin
adults previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

vuxna som inte tidigare vaccinerats med 23-valent pneumokockpolysackaridvaccin
adults not previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

samtidig administrering av prevenar 13 och 23-valent pneumokockpolysackaridvaccin har inte studerats.
concomitant administration of prevenar 13 and 23-valent pneumococcal polysaccharide vaccine has not been studied.

i enlighet med allmänna riktlinjer gavs därefter en engångsdos 23-valent pneumokockpolysackaridvaccin.
as per general recommendations, a single dose of 23-valent pneumococcal polysaccharide vaccine was subsequently administered.

totalt sett observerades inga signifikanta skillnader i biverkningsfrekvensen när prevenar 13 gavs till vuxna som tidigare vaccinerats med pneumokockpolysackaridvaccin.
overall, no significant differences in frequencies of adverse reactions were seen when prevenar 13 was given to adults previously vaccinated with the pneumococcal polysaccharide vaccine.

i enlighet med allmänna riktlinjer gavs en engångsdos 23-valent pneumokockpolysackaridvaccin en månad efter den fjärde dosen prevenar 13.
as per general recommendations, a single dose of 23-valent pneumococcal polysaccharide vaccine was administered 1 month after the fourth dose of prevenar 13.

immunogenicitet och säkerhet för prevenar 13 har visats hos vuxna 18 år och äldre, även hos personer som tidigare vaccinerats med ett pneumokockpolysackaridvaccin.
immunogenicity and safety of prevenar 13 has been demonstrated in adults aged 18 years and older including those previously vaccinated with a pneumococcal polysaccharide vaccine.

patienter som fick två eller fler tidigare doser 23-valent pneumokockpolysackaridvaccin visade likartat immunsvar jämfört med patienter som fick en enstaka tidigare dos.
subjects who received two or more previous doses of 23-valent pneumococcal polysaccharide vaccine showed a similar immune response compared with subjects who received a single previous dose.

i en direkt jämförande prövning med vuxna i åldern 60–64 år, fick deltagarna en engångsdos av antingen prevenar 13 eller 23-valent pneumokockpolysackaridvaccin.
in a head-to-head, comparative trial conducted in adults aged 60-64 years, subjects received a single dose of either prevenar 13 or 23-valent pneumococcal polysaccharide vaccine.

i en dubbelblind, placebokontrollerad, randomiserad klinisk studie på vuxna patienter med psoriasisartrit, erhöll 184 patienter också multivalent pneumokockpolysackaridvaccin under 4:e behandlingsveckan.
in a double blind, placebo controlled, randomised clinical study in adult patients with psoriatic arthritis 184 patients also received a multivalent pneumococcal polysaccharide vaccine at week 4.

i en placebo-kontrollerad klinisk studie på patienter med reumatoid artrit påvisades ingen skillnad i antikroppssvar mellan cimzia- och placebogrupperna när pneumokockpolysackaridvaccin och influensavaccin gavs samtidigt med cimzia.
in a placebo-controlled clinical trial in patients with rheumatoid arthritis, similar antibody response between cimzia and placebo treatment were observed when the pneumococcal polysaccharide vaccine and influenza vaccine were administered concurrently with cimzia.

de flesta psoriasisartritpatienterna som erhöll enbrel i denna studie fick effektiv b-cells immunrespons mot pneumokockpolysackaridvaccin, medan titrarna i aggregaten var moderat lägre och ett fåtal patienter hade två gånger förhöjda titrar jämfört med patienter som inte erhöll enbrel.
in this study most psoriatic arthritis patients receiving enbrel were able to mount effective b-cell immune response to pneumococcal polysaccharide vaccine, but titers in aggregate were moderately lower and few patients had two-fold rises in titers compared to patients not receiving enbrel.

hos vuxna i åldern 60-64 år var gmt mätt med opa för prevenar 13 non-inferior till gmt mätt med opa för 23-valent pneumokockpolysackaridvaccin mot de tolv serotyper som är gemensamma för de båda vaccinerna.
in adults aged 60-64 years, opa gmts to prevenar 13 were non-inferior to the opa gmts elicited to the 23-valent pneumococcal polysaccharide vaccine for the twelve serotypes common to both vaccines.

barn vaccinerades med prevenar (3 doser med en månads mellanrum från 2 månaders ålder), 46 av dessa barn fick dessutom ett 23-valent pneumokockpolysackaridvaccin vid 15-18 månaders ålder.
children were vaccinated with prevenar (3 doses one month apart from the age of 2 months), 46 of these children also received a 23-valent pneumococcal polysaccharide vaccine at the age of 15-18 months.